Johnson & Johnson's Strategic Pivot: Oral Psoriasis Drug and MedTech Restructuring

J&J gains FDA approval for oral psoriasis drug ICOTYDE while decentralizing its MedTech division and spinning off orthopedics unit to fuel growth.

Johnson & Johnson is navigating a dual-track strategic evolution, marked by a significant pharmaceutical approval and a sweeping operational overhaul within its medical technology division. These concurrent developments highlight the healthcare giant's efforts to bolster growth across its diverse business segments.

A Landmark Approval in Dermatology

The U.S. Food and Drug Administration (FDA) granted approval on March 19, 2026, for ICOTYDE, Johnson & Johnson's new oral treatment for plaque psoriasis. This authorization introduces a novel therapeutic option that distinguishes itself from established standards of care. Unlike conventional biologic treatments, which are typically administered via injection, ICOTYDE is an IL-23 receptor antagonist delivered in daily pill form—a convenience expected to enhance patient adherence and appeal.

The regulatory decision was supported by robust Phase 3 clinical trial data involving more than 2,500 participants. Results indicated that after a 16-week regimen, approximately 70% of patients achieved clear or almost clear skin according to the Investigator's Global Assessment (IGA) score. Furthermore, about 55% of trial subjects attained a 90% reduction in psoriasis severity, as measured by the Psoriasis Area and Severity Index (PASI 90). The drug is approved for use in adults and adolescents aged 12 years and older.

Financial Ambitions and Market Performance

Financially, Johnson & Johnson has set an ambitious target for the 2026 fiscal year, projecting revenues of approximately $100.5 billion. This figure represents a year-over-year increase of roughly 6.7%. The company's growth strategy leans on a portfolio of 28 distinct platforms and products, each generating over $1 billion in annual sales. Adding to its investment profile, the firm holds the prestigious status of a "Dividend King," having consecutively raised its shareholder payout for more than five decades.

Market sentiment appears favorable regarding the company's strategic direction. The current share price trades about 22% above its 200-day moving average, suggesting investor confidence in its ongoing initiatives.

Overhauling the Medical Technology Business

Parallel to its pharmaceutical advancements, Johnson & Johnson is executing a profound transformation of its MedTech operations. A major decentralization initiative, launched in 2024, reached a key milestone in January 2026. The division now operates under a fully business-unit-led model, a structural shift impacting an estimated 35,000 employees.

This restructuring is accompanied by a planned spin-off of DePuy Synthes Orthopaedics. This unit constitutes nearly 30% of the broader MedTech portfolio. The separation is designed to allow the remaining businesses to sharpen their strategic focus and operate with greater agility in their respective markets, from cardiovascular devices to surgical robotics.

Together, these moves in pharmaceuticals and MedTech illustrate Johnson & Johnson's multifaceted approach to sustaining its leadership in the global healthcare industry.